Introduction
The 2025 ESC/EACTS Guidelines on Valvular Heart Disease represent a pivotal shift in the balance between surgical and percutaneous interventions. While surgical aortic valve replacement (SAVR) remains the gold standard for younger, low-risk patients, the new guidelines expand the role of transcatheter aortic valve implantation (TAVI) and transcatheter edge-to-edge repair (TEER, MitraClip). This evolution reflects both the maturation of percutaneous technologies and mounting evidence supporting their safety and effectiveness across broader patient populations.
TAVI
1. Lower Age Threshold for TAVI
A significant change involves the age threshold. While the 2021 guidelines recommended TAVI primarily for patients ≥75 years, the 2025 update lowers this to
≥70 years (Class I, Level A)
. Surgical replacement is now indicated only for low-risk patients under 70, while patients aged 70–74 require Heart Team evaluation for personalized treatment decisions. This adjustment substantially increases the eligible population for TAVI.
2. Expanding Interventions for Asymptomatic Patients
Previously, the 2021 guidelines required asymptomatic patients with severe high-gradient aortic stenosis to meet multiple “trigger” conditions (such as very high Vmax, elevated BNP levels, or rapid progression) before intervention was justified. The 2025 guidelines now offer a simplified approach:
intervention may be considered (Class IIa, Level A)
in these patients, even without specific triggers, as long as the procedural risk remains low. This change represents a significant shift in approach, recognizing the potential dangers of waiting when patients have severe disease, even without symptoms.
3. Inclusion of Previously Excluded Valve Anatomies
The new guidelines formally approve TAVI for
bicuspid valves (Class IIb, Level B)
in selected high-risk patients with favorable anatomy. Even more significantly, they now permit
TAVI for pure native aortic regurgitation (Class IIb, Level B)
in symptomatic, inoperable patients with suitable anatomy. These conditions were either omitted or discouraged in the 2021 guidelines, representing a clear expansion of percutaneous treatment options.
4. Streamlined Diagnostic and Procedural Workflow
The 2025 document reflects the maturation of TAVI practice. Coronary computed tomography angiography (CCTA) is now accepted as an alternative to invasive angiography when image quality is adequate (Class IIa, Level B). Additionally, the guidelines have narrowed the criteria for percutaneous coronary intervention (PCI), which is now
restricted to lesions ≥90%
in vessels ≥2.5 mm, compared to the previous broader 70% threshold. These changes aim to reduce unnecessary procedures and minimize procedural burden for patients.
5. Antithrombotic Therapy: Simplified Approach
The new guidelines establish that
single antiplatelet therapy (SAPT) is recommended
as the standard approach after TAVI. Conversely, dual antiplatelet therapy (DAPT) is
not recommended
except when there are other specific indications. This straightforward guidance eliminates previous uncertainty and improves patient safety.
| Clinical scenario | 2021 ESC/EACTS | 2025 ESC/EACTS |
|---|---|---|
| Age and risk (tricuspid) | TAVI ≥75 y: I A; SAVR <75 y: I A; 70–75 y: Heart Team | TAVI ≥70 y: I A; SAVR <70 y: I A; 70–74 y: Heart Team |
| Severe symptomatic AS at high risk | TAVI: I A | TAVI: I A |
| Severe asymptomatic AS, high gradient, preserved EF | Intervention: IIa A with specific triggers (BNP↑, Vmax ≥5.5 m/s, rapid progression) | Intervention: IIa A even with just low procedural risk |
| Bicuspid valve | No formal recommendation / selected cases | TAVI: IIb B if increased risk and favorable anatomy |
| Native aortic regurgitation | TAVI not recommended | TAVI: IIb B if symptomatic, inoperable, favorable anatomy |
| Non-transfemoral access | IIb C (may) | IIa B (should) |
| Coronary work-up | ICA standard | Adequate CCTA can replace ICA (IIa B) |
| Associated PCI | PCI to be considered if stenosis ≥70% | PCI to be considered only if stenosis ≥90% (≥2.5 mm) |
| Post-TAVI antithrombotic therapy | SAPT preferred; DAPT acceptable in some cases | SAPT recommended; DAPT not recommended unless other indications |
Critical Appraisal
These changes collectively highlight a significant expansion of percutaneous therapies relative to surgical approaches. While SAVR remains essential for young, low-risk patients and complex anatomical cases, its overall role is diminishing. TAVI has become the predominant option for patients ≥70 years, certain asymptomatic individuals, and even previously excluded conditions such as bicuspid valves and native aortic regurgitation.
This shift represents more than a technological advancement—it marks a conceptual transformation. Percutaneous interventions have evolved from “alternative options” for inoperable cases into mainstream strategies across a broad clinical spectrum. The Heart Team’s role becomes increasingly vital in weighing factors such as long-term prosthesis durability, patient comorbidities, and individual preferences in this rapidly evolving landscape.
TEER
1. Primary Mitral Regurgitation (Degenerative)
In the 2021 guidelines, TEER for PMR was a Class IIb, Level B recommendation—meaning it “may be considered” in symptomatic patients deemed unsuitable for surgery.
2025 Update: TEER has been upgraded to Class IIa, Level B—”should be considered”—for symptomatic patients at high or prohibitive surgical risk with suitable anatomy.
This upgrade is more than just semantic; it establishes TEER as a standard treatment option for the high-risk degenerative population rather than an exceptional measure.
2. Secondary Mitral Regurgitation (Ventricular, “COAPT-like”)
This represents the most significant change in the guidelines. In 2021, TEER carried a Class IIa or IIb indication, varying based on patient selection and optimization of medical therapy.2025 Update: TEER for ventricular secondary MR has been upgraded to Class I, Level A—the strongest possible recommendation, supported by high-quality evidence. It is now recommended for reducing heart failure hospitalizations and improving quality of life in symptomatic patients with suitable anatomy, even after optimal guideline-directed medical therapy (GDMT) and, when indicated, cardiac resynchronization therapy (CRT).
This evolution reflects the enduring impact of the COAPT trial and establishes TEER as a first-line interventional strategy for a substantial subset of heart failure patients.
3. Secondary Mitral Regurgitation (Atrial Form)
The 2025 guidelines introduce a novel differentiation between ventricular SMR (caused by LV dilatation/dysfunction) and atrial SMR (resulting from atrial/annular dilatation with preserved LV function).
- Surgery (mitral repair plus maze and/or LAA closure) is Class IIa, Level B for symptomatic patients who are surgical candidates.
- TEER is Class IIb, Level B for symptomatic patients unsuitable for surgery, after rhythm optimization.
This represents an important conceptual refinement, recognizing that atrial SMR may differ from ventricular forms in both pathophysiology and treatment approach.
Critical Appraisal
These changes collectively mark a significant evolution of TEER from a last-resort option to a cornerstone therapy:
- For PMR, TEER now occupies a well-defined position in the treatment of high-risk patients.
- In ventricular SMR, its elevation to Class I, Level A standard of care transforms how clinicians manage heart failure patients with persistent symptoms.
- For atrial SMR, the guidelines introduce a clear structure previously absent, delineating appropriate circumstances for surgical versus TEER approaches.
While surgical mitral repair continues to be the gold standard for younger, low-risk PMR patients, the reach of percutaneous intervention continues to broaden, mirroring the trajectory seen with TAVI in aortic valve treatment.
| Clinical Scenario | 2021 ESC/EACTS | 2025 ESC/EACTS |
|---|---|---|
| Primary MR (degenerative, high/prohibitive surgical risk) | IIb B – may be considered | IIa B – should be considered |
| Secondary MR – ventricular (functional, COAPT-like) | IIa/IIb depending on selection and GDMT | I A – recommended |
| Secondary MR – atrial form | Not specifically differentiated | Surgery (repair+maze/LAAO): IIa B; TEER: IIb B if not surgical candidate, after rhythm optimization |
| Surgical mitral repair (PMR, low-risk) | Gold standard, Class I | Gold standard, Class I |
Critical Considerations
Durability. Long-term outcomes remain the primary limitation of percutaneous interventions. For TAVI, 5-year results in low-risk trials (e.g., PARTNER 3, Evolut Low Risk) demonstrate noninferiority to SAVR, but uncertainty exists beyond 8–10 years, particularly in younger patients. For TEER, COAPT shows sustained benefit at 5 years, though patient attrition reflects the advanced heart failure population.
Learning curve and volume. Outcomes for both TAVI and TEER strongly correlate with operator and center experience. High-volume centers achieve better procedural success rates and fewer adverse events, supporting the guidelines’ emphasis on Heart Valve Centers.
Patient selection. Appropriate patient selection remains essential. Lifetime management considerations, anatomic suitability, comorbidities, and future treatment options should guide clinical decisions. The 2025 guidelines emphasize the Heart Team’s central role in balancing surgical durability with percutaneous accessibility.
Conclusion
The 2025 ESC/EACTS Guidelines represent a decisive shift in valvular heart disease management, with TAVI and TEER evolving from selective alternatives to mainstream treatments. For aortic stenosis, TAVI’s scope has expanded beyond its traditional boundaries through a lower age threshold, extended indications for asymptomatic patients, and careful inclusion of bicuspid valves and native regurgitation cases. In mitral disease, TEER has progressed from a last-resort option to a standard of care, earning Class I, Level A endorsement for ventricular secondary MR and gaining prominence in high-risk primary MR.
Surgical approaches remain essential—especially for young, low-risk patients and complex anatomical cases—but the balance is clearly shifting toward less invasive interventions. The Heart Team now faces a new clinical landscape where transcatheter therapies serve as core components of evidence-based practice rather than mere alternatives. This transformation stems from technological advancement, stronger clinical evidence, and increasing emphasis on personalized, minimally invasive care.
References
Praz, F., Borger, M. A., Lanz, J., Marin-Cuartas, M., Abreu, A., Adamo, M., … Zamorano, J. L. (2025). 2025 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. Advance online publication.
https://doi.org/10.1093/eurheartj/ehaf194
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., … Zamorano, J. L. (2021). 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 43(7), 561–632.
https://doi.org/10.1093/eurheartj/ehab395
Mack, M. J., Thourani, V. H., Pibarot, P., Hahn, R. T., Genereux, P., Kodali, S. K., … Leon, M. B. (2023). Transcatheter aortic-valve replacement in low-risk patients at five years. New England Journal of Medicine, 389(21), 1949–1960.
https://doi.org/10.1056/NEJMoa2307447
Stone, G. W., Lindenfeld, J., Abraham, W. T., Kar, S., Lim, D. S., Mishell, J. M., … Mack, M. J.; COAPT Investigators. (2018). Transcatheter mitral-valve repair in patients with heart failure. New England Journal of Medicine, 379(24), 2307–2318.
https://doi.org/10.1056/NEJMoa1806640
Carroll, J. D., Vemulapalli, S., Dai, D., Matsouaka, R., Blackstone, E., Edwards, F., … Grover, F. (2017). Procedural experience for transcatheter aortic valve replacement and relation to outcomes: The STS/ACC TVT Registry. Journal of the American College of Cardiology, 70(1), 29–41.
https://doi.org/10.1016/j.jacc.2017.04.056
Sorajja, P., Vemulapalli, S., Feldman, T., Mack, M., Holmes, D. R., Stebbins, A., … Ailawadi, G. (2017). Outcomes with transcatheter mitral valve repair in the United States: An STS/ACC TVT Registry report. Journal of the American College of Cardiology, 70(19), 2315–2327.